Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting
Salarius Pharmaceuticals (NASDAQ: SLRX) announced the acceptance of two abstracts for presentation at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. One focuses on the preclinical compound SP-3164, showing potential therapeutic properties against lymphoma, while the second details a Phase I/II study of seclidemstat and azacitidine for myelodysplastic syndromes and chronic myelomonocytic leukemia, suggesting safety and potential activity. The presentations occur on December 12, 2022, at the Ernest N. Morial Convention Center, New Orleans.
- Acceptance of two abstracts for the ASH Annual Meeting reflects ongoing interest in Salarius' research.
- The SP-3164 compound demonstrated enhanced anti-cancer activity in preclinical models compared to existing therapies.
- Seclidemstat shows promising safety and potential effectiveness in the ongoing trial for myelodysplastic syndromes.
- Limited clinical data available for seclidemstat, with only six patients enrolled in the study so far.
- Potential uncertainties regarding the FDA's response to the ongoing Phase 1/2 trial of seclidemstat due to previous clinical holds.
HOUSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that two abstracts related to the company’s compounds have been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 10-13, 2022 in New Orleans and virtually. One abstract highlights preclinical work by Salarius with SP-3164 and the other highlights clinical work by collaborators at the University of Texas MD Anderson Cancer Center with seclidemstat.
Salarius’ abstract is titled “SP-3164, a Novel Cereblon-Binding Protein Degrader, Shows Activity in Preclinical Lymphoma Models,” concludes that SP-3164 “shows potential attractive therapeutic properties compared to avadomide and to lenalidomide (Revlimid®). SP-3164 showed increased IKZF1 degradation efficiency compared with other molecular glues and significant anti-cancer activity as a monotherapy in an in vivo lymphoma mouse xenograft model.”
MD Anderson Cancer Center’s abstract is titled, “A Phase I/II Study of Seclidemstat, an LSD1Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML),” concludes that in the six patients for whom data are generated, the combination of seclidemstat with azacitidine “seems safe at the current dose levels and shows signs of potential activity. Further enrollment and follow up continues to further explore this combination.”
The abstracts were published today and are now available on the ASH website at www.hematology.org:
SP-3164 Presentation
Abstract #167495
Title: SP-3164, a Novel Cereblon-Binding Protein Degrader, Shows Activity in Preclinical
Session Date: Monday, December 12, 2022
Presentation Time: 6:00 PM - 8:00 PM
Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III
Publication Number: 3996
Location: Ernest N. Morial Convention Center, Hall D
Presenter: Daniela Santiesteban, Ph.D., Director of Targeted Protein Degradation Development, Salarius, Houston
Seclidemstat Presentation
Abstract #170138
Title: A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Session Date: Monday, December 12, 2022
Presentation Time: 6:00 PM-8:00 PM
Session Name: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III
Publication Number: 4391
Location: Ernest N. Morial Convention Center, Hall D
Presenter: Guillermo Montalban-Bravo, M.D., Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
Following presentation at the meeting, the posters will be available on Salarius’ website at www.salariuspharma.com.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Salarius’ product portfolio includes seclidemstat, the company’s lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and certain additional sarcomas that share a similar biology. Seclidemstat has received fast track, orphan drug and rare pediatric disease designations for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with an investigator-initiated Phase 1/2 clinical study in hematologic cancers at MD Anderson Cancer Center. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing program and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). SP-3164 is currently in IND-enabling studies and anticipated to enter the clinic in 2023. For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.
Forward-Looking Statements
This announcement and the referenced presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements may be identified by terms such as “will,” “future,” “believe,” “developing,” “expect,” “may,” “progress,” “potential,” “could,” “look forward,” “might,” “should,” and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: the advantages of seclidemstat (SP-2577) as a treatment for Ewing sarcoma, Ewing-related sarcomas, and other cancers and its ability to improve the life of patients; expected cohort readouts from the company’s clinical trials and expected therapeutic options for SP-2577 and related effects and projected efficacy, including SP-2577’s ability to inhibit LSD1; the future of the company’s Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas following the recently announced suspected unexpected severe adverse reaction (SUSAR) event and resulting partial clinical hold by the U.S. Food and Drug Administration (FDA); the advantages of protein degraders including the value of SP-3164 as a cancer treatment; the timing of clinical trials for SP-3164 and expected therapeutic options for SP-3164 and related effects and projected efficacy; impact that the addition of new clinical sites will have on the development of our product candidates; the timing of our IND submissions to the FDA and subsequent timing for initiating clinical trials; interim data related to our clinical trials, including the timing of when such data is available and made public; our growth strategy; whether the company will develop additional undisclosed cancer-fighting assets in the targeted protein degradation space; expanding the scope of our research and focus to high unmet need patient populations; and the commercial or market opportunity and expansion for each therapeutic option, including the availability and value of a pediatric priority review voucher for in-clinic treatments and potential for accelerated approval. We may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: Seclidemstat’s impact in Ewing sarcoma and as a potential new and less-toxic treatment; expected dose escalation and dose expansion; resolution of the FDA’s partial clinical hold on the company’s Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas following the SUSAR; our ability to resume enrollment in the clinical trial following its review of the available data surrounding the SUSAR; the adequacy of our capital to support our future operations and our ability to successfully initiate and complete clinical trials and regulatory submissions; the ability of, and need for, us to raise additional capital to meet our business operational needs and to achieve its business objectives and strategy; future clinical trial results and the impact of such results on us; that the results of studies and clinical trials may not be predictive of future clinical trial results; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; and other risks described in our filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. The forward-looking statements contained in this announcement and the referenced presentation speak only as of the date of this announcement and the referenced presentation and are based on management’s assumptions and estimates as of such date. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.
CONTACT:
LHA Investor Relations
Kim Sutton Golodetz
kgolodetz@lhai.com
212-838-3777
FAQ
What is the significance of the abstracts accepted for Salarius Pharmaceuticals at the ASH Annual Meeting?
When will Salarius Pharmaceuticals present its research at the ASH Annual Meeting?
What is SP-3164 and its significance for Salarius Pharmaceuticals?
How is seclidemstat being evaluated in clinical trials?
What are the next steps for Salarius Pharmaceuticals in their clinical trials?
